NeoGenomics launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for patients with prostate adenocarcinoma. The approval adds a new, regulated diagnostic product line, which is likely to be viewed positively for the company’s near-term growth prospects.
NeoGenomics launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for patients with prostate adenocarcinoma. The approval adds a new, regulated diagnostic product line, which is likely to be viewed positively for the company’s near-term growth prospects.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
